Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Get Free Report) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 539,600 shares, a decline of 26.7% from the February 13th total of 736,300 shares. Based on an average daily trading volume, of 1,420,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 4.4% of the company’s shares are short sold.
Cyclo Therapeutics Price Performance
Cyclo Therapeutics stock remained flat at $0.70 during trading on Friday. 33,638 shares of the company were exchanged, compared to its average volume of 411,385. The stock has a market capitalization of $23.04 million, a price-to-earnings ratio of -0.78 and a beta of -0.57. Cyclo Therapeutics has a 52-week low of $0.55 and a 52-week high of $1.79. The business’s 50-day moving average price is $0.79 and its 200 day moving average price is $0.73.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Two Sigma Securities LLC purchased a new stake in Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 42,541 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned approximately 0.15% of Cyclo Therapeutics at the end of the most recent reporting period. 68.55% of the stock is owned by hedge funds and other institutional investors.
Cyclo Therapeutics Company Profile
Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.
Featured Stories
- Five stocks we like better than Cyclo Therapeutics
- ESG Stocks, What Investors Should Know
- How to Build the Ultimate Everything ETF Portfolio
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to start investing in penny stocks
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
